Select Language
Glypican 3
Glypican 3 Overview
| English Name | Glypican-3 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 52 | Target Synonym | MXR7，OCI5，GPC3，Glypican-3，Glypican 3，Glypican Proteoglycan 3，GTR2-2，Secreted Glypican-3，OCI-5，SGBS1，DGSX，SGBS，SDYS，SGB，Intestinal protein OCI-5，Heparan Sulphate Proteoglycan |
| Highest Development Stage | Phase 2 Clinical | ||
| English Name | Glypican-3 |
| Target Synonym | MXR7，OCI5，GPC3，Glypican-3，Glypican 3，Glypican Proteoglycan 3，GTR2-2，Secreted Glypican-3，OCI-5，SGBS1，DGSX，SGBS，SDYS，SGB，Intestinal protein OCI-5，Heparan Sulphate Proteoglycan |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 52 |
| Highest Development Stage | Phase 2 Clinical |
Glypican 3 Product List
- Product Category
Protein (23)Cell (3)Beads (2)
- Product Status
Launched (28)
- Species
Human (20)Cynomolgus (4)Mouse (3)Rat (1)
- Tag
His Tag (15)Fc Tag (5)His Tag & Avi Tag (1)Llama IgG Fc Tag (2)- (5)
- Conjugate
Unconjugated (14)Biotin-labeled (1)FITC Labeled (2)PE Labeled (2)APC Labeled (3)AF488 Labeled (1)- (5)
Total: 28
- 1
- 2
- 3
Glypican 3 Background
Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.
Glypican 3 Synonyms
GPC3,OCI5,Glypican-3,GTR2-2,MXR7,DGSX,SDYS ,SGB,SGBS,SGBS1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
| BOS-342 | PRS-342; BOS-342; PRS-342/BOS-342 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Carcinoma, Hepatocellular | Details |
| BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Liver Neoplasms; Carcinoma, Merkel Cell; Lung Neoplasms; Carcinoma, Squamous Cell; Liposarcoma, Myxoid; Carcinoma, Hepatocellular | Details |
| AZD-9793 | AZD9793; AZD-9793 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
| CAR-T Cell Therapy Targeting GPC3(Pla General Hospital) | Phase 2 Clinical | Pla General Hospital | Carcinoma, Hepatocellular | Details | |
| MRG-006A | MRG-006A; MRG-006; MRG006A | Phase 2 Clinical | Lepu Biopharma Co Ltd, Shanghai Miracogen Inc | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
| C-CAR031 | C-CAR031; AZD-7003; TC-CAR-031; TC-CAR031; C-CAR-031 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
| NY-303 | NY-303 | Phase 2 Clinical | NAYA Biosciences Inc | Solid tumours; Carcinoma, Hepatocellular | Details |
| AZD-5851 | AZD-5851; AZD5851 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | Details |
| SAR-444200 | SAR-444200 | Phase 2 Clinical | Sanofi | Solid tumours; Neoplasms | Details |
| CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| CAR-GPC3 T-cell (Drum Tower Hospital) | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details | |
| GPC3 CAR-T therapy (Hrain Biotechnology) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details | |
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
| GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001; Ori-C101（OriCell） | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
| ECT-204 | JWATM-204; ECT-204 | Phase 2 Clinical | Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Codrituzumab | GC-33; RG-7686; RO-5137382 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
| GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Rhabdomyosarcoma; Liver Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Wilms Tumor; Liposarcoma; Carcinoma, Hepatocellular; Endodermal Sinus Tumor | Details |
| Anti-GPC3 CAR T-cell therapy (Carbiogene Therapeutics) | CBG166; CBG-166 | Phase 1 Clinical | Nanjing University, Carbiogene Therapeutics Co Ltd | Carcinoma, Hepatocellular | Details |
| GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details | |
| anti-GPC3 CAR T-cell therapy (National Institutes of Health Clinical Center) | Phase 1 Clinical | National Institutes Of Health Clinical Center (Cc) | Carcinoma, Hepatocellular | Details | |
| anti-GPC3 CAR T-cell therapy (Nanjing Drum Tower Hospital) | Phase 1 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details | |
| GPC3-T2-CAR-T | GPC3-T2-CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Hepatocellular | Details |
| EU-307 | EU307 | Phase 1 Clinical | Eutilex | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| Ori-CAR-002 | Ori-CAR-002; GPC3-CAR-Ori2 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
| SENTI-301 | SENTI-301; SENTI-301A; SN301A | Phase 1 Clinical | Senti Biosciences Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| BAY-3547926 | BAY3547926; BAY-3547926 | Phase 1 Clinical | Bayer AG | Carcinoma, Hepatocellular | Details |
| MT-303(Myeloid) | MT-303(Myeloid) | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma, Hepatocellular | Details |
| 68Ga-aGPC3-scFv/Fab | 68Ga-aGPC3-scFv/Fab | Phase 1 Clinical | Wuhan Union Hospital | Liver Neoplasms | Details |
| BGB-B2033 | BGB-B2033; BGB-B-2033 | Phase 1 Clinical | Beigene Guangzhou Biologics Manufacturing Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| BC-2027 | BC2027; BC-2027 | Phase 1 Clinical | Wuxi BioCity | Liver Neoplasms; Solid tumours | Details |
| JMT-106 | JMT106; JMT-106 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
| AST-201 (Aptamer Sciences) | AST-201(Aptamer Sciences) | Phase 1 Clinical | Aptamer Sciences Inc | Liver Neoplasms; Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms | Details | |
| RYZ-801 | RYZ-801(225Ac); RYZ-801; ABZ-706; 225Ac-GPC3 | Phase 1 Clinical | PeptiDream Inc, RayzeBio Inc | Carcinoma, Hepatocellular | Details |
| NWRD-06 | NWRD-06; NWRD06 | Phase 1 Clinical | Newish Technology (Beijing) Co Ltd | Carcinoma, Hepatocellular | Details |
| GKL-006 | GKL-006; GKL006 | Phase 1 Clinical | Beijing Gene Key Life Technology Co Ltd | Pancreatic Neoplasms; Carcinoma, Hepatocellular | Details |
| GPC3-targeted CAR-T (Peking University) | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | Details | |
| CAR (hYP7)-T cells (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Carcinoma, Hepatocellular | Details | |
| QLS-31903 | QLS31903; QLS-31903 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| IM-83 CAR-T cell therapy | IM-83; IM83 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Liver Neoplasms; Neoplasms; Osteosarcoma; Carcinoma, Hepatocellular | Details |
| CT-017 | CT-017 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
| JWATM-214 | JWATM-214; JWATM214 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| TH-012(Bangentai Biomedical) | TH-012 | Phase 1 Clinical | Shandong Bangentai Biomedical Tech Group Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
| B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
| CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
| ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| TAK-102 | TAK-102; NIB-102 | Phase 1 Clinical | Noile-Immune Biotech Inc | Solid tumours | Details |
| HRAIN-011 | HRAIN-011 | Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details |
| Anti-GPC3-IRDye800CW | Clinical | Chinese Academy Of Sciences | Details |
Product Reviews
G***I2025-11-07
0People LikeACRO's Bio-CD28 has almost no batch differences. Finished using a certain lot, then purchased again, was worried about the need to optimize again, but it worked out smoothly. Saving time and effort!- 1***62019-10-11 3People LikeGPC3 is also currently a popular target for solid tumors. I bought this product to detect the positive rate of CAR-T cells. The result was the same with the one performed using our own purified expressed protein (added hFc tag, which requires fluorescent labeled secondary antibodies). But no need to dye for secondary antibodies, so this one from ACRO was more convenient.
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main